Xiaoxin Liang

SEP 9, 2026 · JOURNAL ARTICLE

GV21 enables ultrasound molecular imaging of tumor cell-associated VEGFR2 for early therapy assessment

Materials Today Bio

First-in-concept preclinical development of a novel imaging agent with no clinical efficacy or safety data, surrogate endpoint (imaging signal), and no controlled comparison of therapeutic outcomes.